US OptionsDetailed Quotes
SGMO241115P4000
- 1.25
- +0.10+8.70%
15min DelayClose Nov 12 15:59 ET
1.25High1.25Low
1.25Open1.15Pre Close1.00K Volume48 Open Interest4.00Strike Price125.00KTurnover513.38%IV-1.48%PremiumNov 15, 2024Expiry Date1.29Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7576Delta0.2704Gamma1.90Leverage Ratio-0.0717Theta-0.0002Rho-1.44Eff Leverage0.0007Vega
Sangamo Therapeutics Stock Discussion
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
3
$Sangamo Therapeutics (SGMO.US)$ Third Quarter 2024 Financial Results
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
2
5
$Sangamo Therapeutics (SGMO.US)$
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...
1
$Sangamo Therapeutics (SGMO.US)$
Looking like it's coming together.
10 dollar target from HCW today. GLTA
Looking like it's coming together.
10 dollar target from HCW today. GLTA
4
2
$Sangamo Therapeutics (SGMO.US)$ .. drop to below 1.5.. sell now later buy once drop down.
1
$Sangamo Therapeutics (SGMO.US)$ New 52 Wk high🥂💸
1
2
$Sangamo Therapeutics (SGMO.US)$ Go baby go!
1
$Sangamo Therapeutics (SGMO.US)$
Check this out.... Cost of ERT therapy for lifetime for a Fabry patient. Dutch study. The numbers will surprise you!!!
https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-29
Check this out.... Cost of ERT therapy for lifetime for a Fabry patient. Dutch study. The numbers will surprise you!!!
https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-29
$Sangamo Therapeutics (SGMO.US)$
price consolidating. some people taking profits. Fabry deal when announced should put us over $2 I think. Still holding full position at 0 .68 patiently holding for a big payday next year sometime I think.
price consolidating. some people taking profits. Fabry deal when announced should put us over $2 I think. Still holding full position at 0 .68 patiently holding for a big payday next year sometime I think.
2
No comment yet
Kaibu Wang : What will cause after
Jaguar8 OP Kaibu Wang : It’s only a prospectus. They may sell common stocks from time to time once registration becomes effective. It means just be cautious
Kaibu Wang Jaguar8 OP : Thanks man